DIFFERENCES IN THE EVENT OF OVARIAN CYST use of tamoxifen BREAST CANCER PATIENTS WITH ULTRASOUND EXAMINATION
ABSTRACT: Background:Breast cancer is a main health problem in women worldwide. It is the most frequent cancer in women in US and the 2nd cause for malignancyrelated mortalities. It is the 2nd most frequent cancer in Indonesia, only after cervix uterine cancer. Tamoxifen classifiedin Selective Estrogen Receptor Modulator (SERM) is a competitive inhibitor of estradiol partial agonist at the estrogen receptor, which use is reccomended for hormonal ajuvan given for 5 years for every woman with positive hormonal receptor breast cancers. Long term Tamoxifen has adverse effect namely increasing in risk for ovarian cyst development. To evaluate the ovarium in breast cancer patients who received Tamoxifen, transvaginal ultrasound can be used. Objectives:Assessdifferences inthe occurrence ofovarian cysts inbreastcancerpatients withTamoxifenuse Methods:Observationalanalyticstudy, case-control design. Consecutivesampling,samplenumber60subjectsdividedinto30subjectsas agroupof caseswithovariancystsand30subjectswithoutovariancystsas a control groupand statistical hypothesis testing using Chi square analysis.The discovery ofovarian cystsperformed usingtransvaginalultrasonography. This research wasperformed at theHospitalRadiologydr.SardjitoYogyakartawhichhave beenbased onthe criteria. Result:Obtained 60 subjects with breast cancer, 30 subjects designated as case group (with ovarian cysts), 30 subjects as a control group (without ovarian cysts). There are 73.3% of subjects in the group of cases with ovarian cysts who use Tamoxifen. With a statistical analysis of figures obtained Chi square p <0.05. Average duration of use Tamoxifen 13.2143 months with p> 0.05. Conclusion:There are differences inthe incidence ofovarian cysts inbreastcancerpatients withTamoxifenuse. There were nosignificantresultsbetweenthe olduse ofTamoxifenwithovariancystsevents
